Search Results - "DRIESSEN, Christoph"

Multiple myeloma: patient outcomes in real‐world practice by Yong, Kwee, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Raab, Marc S., Schoen, Paul, Cavo, Michele

“…Summary With increasing number of therapies available for the treatment of multiple myeloma, it is timely to examine the course of patients' journeys. We…”
Get full text

Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors by Besse, Andrej, Besse, Lenka, Kraus, Marianne, Mendez-Lopez, Max, Bader, Jürgen, Xin, Bo-Tao, de Bruin, Gerjan, Maurits, Elmer, Overkleeft, Herman S, Driessen, Christoph

“…Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5…”
Get more information

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma by Besse, Lenka, Kraus, Marianne, Besse, Andrej, Driessen, Christoph, Tarantino, Ignazio

“…Chemotherapy resistance is still a major problem in the treatment of patients with non-small-cell-lung carcinoma (NSCLC), and novel concepts for the induction…”
Get full text

Management of cardiovascular risk in patients with multiple myeloma by Plummer, Chris, Driessen, Christoph, Szabo, Zsolt, Mateos, María-Victoria

“…Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological cancers. It predominantly affects elderly people; median age at…”
Get full text

Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors by Schwestermann, Jonas, Besse, Andrej, Driessen, Christoph, Besse, Lenka

“…Virtually all patients with multiple myeloma become unresponsive to treatment with proteasome inhibitors over time. Relapsed/refractory multiple myeloma is…”
Get full text

Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events by ARASTU-KAPUR, Shirin, ANDERL, Janet L, KIRK, Christopher J, KRAUS, Marianne, PARLATI, Francesco, SHENK, Kevin D, LEE, Susan J, MUCHAMUEL, Tony, BENNETT, Mark K, DRIESSEN, Christoph, BALL, Andrew J

“…Bortezomib (Velcade), a dipeptide boronate 20S proteasome inhibitor and an approved treatment option for multiple myeloma, is associated with a…”
Get full text

Multiple myeloma: practice patterns across Europe by Raab, Marc S., Cavo, Michele, Delforge, Michel, Driessen, Christoph, Fink, Leah, Flinois, Alain, Gonzalez‐McQuire, Sebastian, Safaei, Reza, Karlin, Lionel, Mateos, Maria‐Victoria, Schoen, Paul, Yong, Kwee

“…Summary Real‐world data describing management of patients with multiple myeloma are limited. A European (Belgium, France, Germany, Italy, Spain, Switzerland,…”
Get full text

A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis by Besse, Lenka, Besse, Andrej, Mendez-Lopez, Max, Vasickova, Katerina, Sedlackova, Miroslava, Vanhara, Petr, Kraus, Marianne, Bader, Jürgen, Ferreira, Renan B, Castellano, Ronald K, Law, Brian K, Driessen, Christoph

Get full text

European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when by Caers, Jo, Garderet, Laurent, Kortüm, K Martin, O'Dwyer, Michael E, van de Donk, Niels W C J, Binder, Mascha, Dold, Sandra Maria, Gay, Francesca, Corre, Jill, Beguin, Yves, Ludwig, Heinz, Larocca, Alessandra, Driessen, Christoph, Dimopoulos, Meletios A, Boccadoro, Mario, Gramatzki, Martin, Zweegman, Sonja, Einsele, Hermann, Cavo, Michele, Goldschmidt, Hartmut, Sonneveld, Pieter, Delforge, Michel, Auner, Holger W, Terpos, Evangelos, Engelhardt, Monika

“…The diagnosis of multiple myeloma can be challenging, even for experienced physicians, and requires close collaboration between numerous disciplines…”
Get full text

The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance by Ferguson, Ian D., Patiño-Escobar, Bonell, Tuomivaara, Sami T., Lin, Yu-Hsiu T., Nix, Matthew A., Leung, Kevin K., Kasap, Corynn, Ramos, Emilio, Nieves Vasquez, Wilson, Talbot, Alexis, Hale, Martina, Naik, Akul, Kishishita, Audrey, Choudhry, Priya, Lopez-Girona, Antonia, Miao, Weili, Wong, Sandy W., Wolf, Jeffrey L., Martin, Thomas G., Shah, Nina, Vandenberg, Scott, Prakash, Sonam, Besse, Lenka, Driessen, Christoph, Posey, Avery D., Mullins, R. Dyche, Eyquem, Justin, Wells, James A., Wiita, Arun P.

“…The myeloma surface proteome (surfaceome) determines tumor interaction with the microenvironment and serves as an emerging arena for therapeutic development…”
Get full text

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) by Palumbo, Antonio, Bringhen, Sara, Ludwig, Heinz, Dimopoulos, Meletios A., Bladé, Joan, Mateos, Maria V., Rosiñol, Laura, Boccadoro, Mario, Cavo, Michele, Lokhorst, Henk, Zweegman, Sonja, Terpos, Evangelos, Davies, Faith, Driessen, Christoph, Gimsing, Peter, Gramatzki, Martin, Hàjek, Roman, Johnsen, Hans E., Leal Da Costa, Fernando, Sezer, Orhan, Spencer, Andrew, Beksac, Meral, Morgan, Gareth, Einsele, Hermann, San Miguel, Jesus F., Sonneveld, Pieter

“…Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of…”
Get full text

Autophagy Promotes MHC Class II Presentation of Peptides from Intracellular Source Proteins by Dengjel, Jörn, Schoor, Oliver, Fischer, Rainer, Reich, Michael, Kraus, Marianne, Müller, Margret, Kreymborg, Katharina, Altenberend, Florian, Brandenburg, Jens, Kalbacher, Hubert, Brock, Roland, Driessen, Christoph, Rammensee, Hans-Georg, Stevanovic, Stefan, Cresswell, Peter

“…MHC-peptide complexes mediate key functions in adaptive immunity. In a classical view, MHC-I molecules present peptides from intracellular source proteins,…”
Get full text

High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex by Zhou, Xiang, Besse, Andrej, Peter, Jessica, Steinhardt, Maximilian Johannes, Vogt, Cornelia, Nerreter, Silvia, Teufel, Eva, Stanojkovska, Emilia, Xiao, Xianghui, Hornburger, Hannah, Haertle, Larissa, Lopez, Max Mendez, Munawar, Umair, Riedel, Angela, Han, Seungbin, Maurits, Elmer, Overkleeft, Herman S, Florea, Bogdan, Einsele, Hermann, Kortüm, K Martin, Driessen, Christoph, Besse, Lenka, Rasche, Leo

“…Optimal carfilzomib dosing is a matter of debate. We analyzed the inhibition profiles of proteolytic proteasome subunits β5, β2 and β1 after low-dose (20/27…”
Get full text

Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study by Silzle, Tobias, Kahlert, Christian R, Albrich, Werner C, Nigg, Susanne, Demmer Steingruber, Ruth, Driessen, Christoph, Fischer, Stefanie

“…Currently available messenger ribonucleic acid (mRNA)-based vaccines against coronavirus disease (COVID-19) have been shown to be effective even in highly…”
Get full text

Complete hematological and major molecular response through treatment with low‐dose Interferon alpha 2a in high‐risk polycythemia vera patient: a case report by Driessen, Christoph, Noppen, Christoph, Boonen, Georg, Drewe, Juergen

“…Low‐dose interferon‐α 2a treatment may be considered as an alternative to cytoreductive therapy with hydroxyurea or regularly dosed interferon in high‐risk…”
Get full text

Acupuncture in chemotherapy-induced dysgeusia (AcuDysg): study protocol of a randomised controlled trial by Huber, Christine, Zhang, Linxin, Schlaeppi, Marc, Müller, Twyla, Roll, Stephanie, Voiss, Petra, Barth, Jürgen, Driessen, Christoph, Witt, Claudia M

“…IntroductionDysgeusia is a common side effect of chemotherapy in patients with cancer, but to date, there is no effective treatment. Many patients with cancer…”
Get full text

Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) by Schulz, Holger, Rehwald, Ute, Morschhauser, Franck, Elter, Thomas, Driessen, Christoph, Rüdiger, Thomas, Borchmann, Peter, Schnell, Roland, Diehl, Volker, Engert, Andreas, Reiser, Marcel

“…Because nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) express CD20, rituximab may be used as a nonmutagenic treatment option to avoid late toxicities…”
Get full text

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma by Kliebhan, Johannes, Besse, Andrej, Kampa‐Schittenhelm, Kerstin, Schittenhelm, Marcus, Driessen, Christoph

“…The p53 mutation R273H in tumor cells leads to increased glucose uptake, lactic acidosis, and accelerated tumor growth, as was previously shown in mice. We…”
Get full text

The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells by Kraus, Marianne, Bader, Juergen, Geurink, Paul P, Weyburne, Emily S, Mirabella, Anne C, Silzle, Tobias, Shabaneh, Tamer B, van der Linden, Wouter A, de Bruin, Gerjan, Haile, Sarah R, van Rooden, Eva, Appenzeller, Christina, Li, Nan, Kisselev, Alexei F, Overkleeft, Herman, Driessen, Christoph

“…Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome…”
Get full text

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08) by Driessen, Christoph, Kraus, Marianne, Joerger, Markus, Rosing, Hilde, Bader, Jürgen, Hitz, Felicitas, Berset, Catherine, Xyrafas, Alexandros, Hawle, Hanne, Berthod, Gregoire, Overkleeft, Hermann S, Sessa, Christiana, Huitema, Alwin, Pabst, Thomas, von Moos, Roger, Hess, Dagmar, Mey, Ulrich J M

“…Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in multiple myeloma. The Human Immunodeficieny Virus protease…”
Get full text